Thank you, Ryan.
second ambitious report position achievements held where for us growth its quarter, Day well achieve we to webcast the I goals believe company during coming very we our During first in pleased articulated. this the outlined am years. that period Investor we the have the to that our plan
XX% growth CAGR in and strategy advance into to has Day, our early the maximize growth over during Investor XX% seeks business, programs each our expanded EBITDA Lifecore the This X-pronged customer during our days, this business discussed increase new pipeline seeks towards and margins though through few we a action of the over revenue commercialization, strategy years. put existing its within quarter. And our that strategy to As drive is program business next to a development efforts. was company finally, in progress made second to development drive arm
first great maximize progress strategic our with customers fill/finish made company goal, operations. the and the to both our in to respect business our fermentation existing With
on our that customers company to During with meet their worked they supply the demand. our working have quarter, of after customers second changing with chain their their closely one needs meet to senior comment team ensure to supply base. trust adequate represents Recently, our to are multinational a business." every challenge, at we the a strength executive that our This establish large "Lifecore customer our support of near-term a of is one pharma with said, working
of which the towards development of to in is advancement development our our us area pipeline growth, focus brings This achieving commercialization. our -- second
continue programs to have the maintain to XXXX. by and status late-stage all XX approval We potential achieve commercial
that no will generate substantial midterm. reach is the line, modest there subset for they guarantee in finish a group each this While the growth company even and the could of impactful
new focus growth, for now our driving expanded is through to which efforts. third business I'll our business development company area to of move
to with development We and by pipeline our programs. grew X collaborate clients continue our
and target strategy creating market, Investor support As we Day, we our new expand made in more have pipeline. discussed technology investments have organization our to agile on we expanding capitalizing our to sales deployed a during a
In know you effort to focused include the products committed in only across to Lifecore viscous on As to is formulations significant past, modalities. complex, other formulations. focus was an of team growth, new its many multiple and our expanding achieve highly
has aggressively As qualify recent months team in our significantly BD pipeline to new than project more grown the our a advance result, working with and XX opportunities.
an qualifying leads with closure. in large deployment we the expanded we companies towards addition, are have of progressing seen number being and our multinational plan, increase business pharmaceutical In development where opportunities evaluated
pipeline customer we expanded and are team continue expect activity that level that will fuel of our impactful in will expanded years with for new and programs and to an our to We increased confident diverse result more base come.
have business further team expand adopted across organization. level to I team at our business, market. awareness approach the brand driving development begun platform the of company to effort, and new a this To closely strengthen BD working with highest and support engagement our has our our including
and our Lifecore of do sells. needs hard needs to ourselves position of all customers at and working customers' at arise. philosophy committed we for we new heart opportunities This our are a at is as to the the meeting Lifecore, Everyone
mentioned X new Nirsum on Nirsum with Lifecore new lead pipeline. NRS-XXX. early-stage development Nirsum's customers. deals to programs agreements project As with of this focused announced one we candidate, of our period development we provide new These to Earlier these month, its clinical I the Laboratories. during CDMO selected supporting added earlier, signed services
currently Lifecore syringes Nirsum NRS-XXX clinical the which is novel and clinical development. discovered for Pursuant NRS-XXX, of agreement, for is a II to is filled internally and the use in treatment Nirsum, with use NRS-XXX. Phase development signed of entering disorder. alcohol provide by will use newly owned disorder wholly opioid
to Nirsum their excited appreciative with collaborate are us of customers to these activities. entrusted on team to them add has list our and that growing We
the filler, these revenue-generating Supplementing the the compliance the and This expanded high-speed capacity and range capabilities and a annually and X-head capability pharmaceutical multipurpose isolator second filler. our cartridges, available technology to of that has vials, doubled expect has state-of-the-art opportunities world's a capacity The isolator which to syringes business. fill project and million leading support. the quarter, company's would from during efforts provides $XXX installed and company demand can leading approximately the companies CDMO we is the increased
company's culture. our has his compliance take of within Finally, second leadership named maintain Development experience. will an during and extensive President Services, strong transformation, pharmaceutical experienced reputation to quarter, experience with created significant of for appointment, part excellence Quality which Thomas conjunction Thomas Senior which regulatory finance productivity performance-driven strong the professional of been brings company's talent operational of this our operations leadership of Jackie her we President our Klecker we a advantage Executive Guldager industry Operations, as as appointment with believe background, area. newly a in and the will In position, the Vice Vice him team CDMO and added with help drive
and of quality. organizational we strategically and will as Lifecore on allow both This evolution This strengths us growth. important leverage bifurcates our embark and quality operations key but functions, exceptional a and sustaining operational of the reducing expenses Jackie natural critically the phase for change of advancing Thomas objectives our next to representing maintaining
great an from as made In development would the doing transformational to are improved a targeting, margins the past changes that like to we executing manufacturing of strategy. well commercial of will and adjusted be as EBITDA. in to against Lifecore opportunities year, that closing, significant drug we and well plan customers changes are In segment commercial enhanced designed to serve leadership significantly revenues able the reemphasize including we increased we capabilities new have maximize customers us front growth and ranging best to that our to as These at I objectives and been the as achieve believe larger aggressive are so, existing serve that market. over our
for company open and long concludes We tracking growth for in strategy term. today. prepared with are progress of leadership the you in increasingly the Operator, for that the our and confident call half pleased mid may fiscal our now and success first remarks are our priorities This near, XXXX are the questions.
